Table 2 Baseline demographics and characteristics
(N = 633)a | |
|---|---|
Mean (SD) age, y | 45.4 (11.7) |
Female, n (%) | 540 (85.3) |
Mean (SD) BMI, kg/m2 | 24.7 (4.8) |
Headache diagnosis history, n (%)b | |
CM | 580 (91.6) |
Migraine | 453 (71.6) |
Medication overusec | 229 (36.2) |
Tension headache | 155 (24.5) |
Chronic daily headache | 82 (13.0) |
Chronic tension-type headache | 76 (12.0) |
Menstrual headache or menstrual migraine | 63 (10.0) |
Stress headache | 57 (9.0) |
Intractable/refractory migraine of headache | 46 (7.3) |
Cluster headache | 15 (2.4) |
Sinus headache | 7 (1.1) |
Hemicrania continua | 1 (0.2) |
Newly daily persistent headache | 1 (0.2) |
Other | 16 (2.5) |
Mean (SD) age of onset of headache, yd | 18.2 (9.9) |
Mean (SD) time since first diagnosis of migraine, mo | 242.9 (154.2) |
Mean (SD) time since first diagnosis of CM, mo | 67.4 (96.1) |
Previous headache medications, n (%)b | |
Beta blockers | 453 (71.6) |
Antidepressants | 445 (70.3) |
Antiepileptics | 441 (69.7) |
Calcium channel blockers | 189 (29.9) |
Botulinum toxin | 63 (10.0) |
Most frequently prescribed acute headache medications in the last 26 weeks before baseline and being used at baseline, n (%) | |
Sumatriptan | 152 (24.0) |
Ibuprofen | 123 (19.4) |
Zolmitriptan | 79 (12.5) |
Rizatriptan | 77 (12.2) |
Most frequently prescribed preventive headache medication in 26 weeks before baseline and being used at baseline, n (%) | |
Topiramate | 107 (16.9) |